



# Identification of Novel Spx Regulatory Pathways in *Bacillus subtilis* Uncovers a Close Relationship between the CtsR and Spx Regulons

✉ Daniel F. Rojas-Tapias,<sup>a\*</sup> ✉ John D. Helmann<sup>a</sup>

<sup>a</sup>Department of Microbiology, Cornell University, Ithaca, New York, USA

**ABSTRACT** In *Bacillus subtilis*, the Spx transcription factor controls a large regulon in response to disulfide, heat, and cell wall stresses. The regulatory mechanisms that activate the Spx regulon are remarkably complex and involve changes in transcription, proteolysis, and posttranslational modifications. To identify genes involved in Spx regulation, we performed a transposon screen for mutations affecting expression of *trxB*, an Spx-dependent gene. Inactivation of *ctsR*, encoding the regulator of the Clp proteases, reduced *trxB* expression and lowered Spx levels. This effect required ClpP, but involved ClpC rather than the ClpX unfoldase. Moreover, cells lacking McsB, a dual function arginine kinase and ClpCP adaptor, largely reverted the *ctsR* phenotype and increased *trxB* expression. The role of McsB appears to involve its kinase activity, since loss of the YwE phosphoarginine phosphatase also led to reduced *trxB* expression. Finally, we show that Spx is itself a regulator of the *ctsR* operon. Altogether, this work provides evidence for a role of CtsR regulon members ClpC, ClpP, and McsB in Spx regulation and identifies a new feedback pathway associated with Spx activity in *B. subtilis*.

**IMPORTANCE** In *Bacillus subtilis*, the Spx transcription factor is proteolytically unstable, and protein stabilization figures prominently in the induction of the Spx regulon in response to oxidative and cell envelope stresses. ClpXP is largely, but not entirely, responsible for Spx instability. Here, we identify ClpCP as the protease that degrades Spx under conditions that antagonize the ClpXP pathway. Spx itself contributes to activation of the *ctsR* operon, which encodes ClpC as well as the McsB arginine kinase and protease adaptor, thereby providing a negative feedback mechanism. Genetic studies reveal that dysregulation of the CtsR regulon or inactivation of the YwE phosphoarginine phosphatase decreases Spx activity through mechanisms involving both protein degradation and posttranslational modification.

**KEYWORDS** *Bacillus subtilis*, Clp protease, Spx, proteolysis, stress response

Spx belongs to the ArsC family of transcriptional regulators and is best known as the master regulator of the disulfide stress response in *Bacillus subtilis* (1). Spx consists of two major domains: one is formed by the N-terminal and C-terminal parts of the protein, and one is formed by its central region. The first domain contains a Cys-X-X-Cys (CXXC) redox-sensing switch that modulates Spx activity upon formation of an intramolecular disulfide bond (2). The central domain is involved in binding to the  $\alpha$ -C-terminal domain (CTD) of RNA polymerase (3). Spx controls the expression of well more than 200 genes, including those involved in the synthesis of bacillithiol and cysteine and the thioredoxin system (1, 4).

Spx is encoded in a bicistronic operon, along with a putative acetyltransferase, and its expression is regulated by at least three different promoters ( $P_A$ ,  $P_{M1}$ , and  $P_B$ ) that are dependent on different holoforms of the RNA polymerase (5–7). Expression of *spx*

**Citation** Rojas-Tapias DF, Helmann JD. 2019. Identification of novel Spx regulatory pathways in *Bacillus subtilis* uncovers a close relationship between the CtsR and Spx regulons. *J Bacteriol* 201:e00151-19. <https://doi.org/10.1128/JB.00151-19>.

**Editor** Tina M. Henkin, Ohio State University

**Copyright** © 2019 American Society for Microbiology. All Rights Reserved.

Address correspondence to John D. Helmann, [jdh9@cornell.edu](mailto:jdh9@cornell.edu).

\* Present address: Daniel F. Rojas-Tapias, Infectious Diseases and Microbiome Program, The Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.

**Received** 24 February 2019

**Accepted** 4 April 2019

**Accepted manuscript posted online** 8 April 2019

**Published** 10 June 2019

from the  $P_A$  promoter, dependent on  $\sigma^A$ , is sufficient to complement an  $\Delta spx$  mutant and for normal regulation in response to disulfide stress (7). The activity of the  $P_A$  promoter is regulated by two protein repressors, PerR and YodB, and is therefore induced by redox or electrophile stress (8). The  $\sigma^M$ -controlled  $P_{M1}$  promoter was recently shown to be critical for induction of the Spx regulon in response to cell wall stress (5). Little is known, however, about the functional role of the  $P_B$  promoter, which is induced as part of the general stress response, as documented in the specific case of phosphate starvation (6).

Under unstressed conditions, Spx levels remain low since the protein is actively proteolyzed via ClpXP; this process is assisted by the adaptor protein YjbH, which is itself under Spx control (9–11). Stabilization of Spx plays a critical role in the induction of the Spx regulon in response to diamide, an electrophilic compound used to generate disulfide stress. Under disulfide stress, Spx is stabilized by aggregation of YjbH (12) and a decrease in ClpXP activity (13). Diamide also triggers oxidation of the redox-sensitive CXXC motif which activates Spx (2). Spx stabilization is also required for the full activation of the Spx regulon in response to cell wall stress. However, this stabilization is mediated by the anti-adaptor protein YirB, which binds YjbH and prevents Spx degradation through ClpXP (14, 15). Interestingly, under cell wall stress, Spx remains in the reduced state; therefore, the contribution of the redox-active disulfide switch appears to be limited under these conditions (5).


Although the *in vivo* mechanisms of Spx activation by stress are fairly well understood, some questions regarding Spx stability and activity remain to be answered. For instance, cells harboring a  $Spx^{C10A}$  or  $Spx^{C10AC13A}$  protein, both unable to form the intramolecular disulfide switch, display different profiles of activation of Spx-controlled genes in response to cell wall and disulfide stress (5). Moreover, Spx accumulates in response to cell wall stress in a YirB-independent manner, which therefore implicates other stabilization mechanisms (14).

In this work, we sought to identify additional regulatory pathways affecting Spx activity. We demonstrate that ClpCP degrades Spx under conditions that antagonize the ClpXP pathway, and this pathway is further activated when the CtsR repressor is inactive. Moreover, Spx itself contributes to activation of the *ctsR* operon, which encodes ClpC as well as the McsB arginine kinase and protease adaptor, thereby providing a negative feedback mechanism that likely involves both protein degradation and posttranslational modification.

## RESULTS AND DISCUSSION

**Dysregulation of the CtsR regulon leads to reduced induction of *trxB*.** We carried out *mariner* transposon mutagenesis to identify novel pathways involved in Spx regulation. For this, we used cells harboring a  $P_{trxB}$ -*lacZ* fusion, which is positively regulated by Spx and serves as a readout of Spx activity. The transposon library was plated on LB plus X-Gal (5-bromo-4-chloro-3-indolyl- $\beta$ -D-galactopyranoside) medium, and light blue or white colonies were selected for further analysis. Transposon-generated mutations that decreased Spx activity included *iolR* (8 independent insertions), *ctsR* (5), *galK* (3), *menH* (3), and *ywIE* (1) (see Table S1 in the supplemental material). In this study, we focus on the *ctsR* gene, as it encodes the master regulator of proteolysis in *B. subtilis* (16, 17) and hence is a potential regulator of Spx stability. Additionally, CtsR was also previously reported to interact with YjbH in yeast two-hybrid experiments (15), and its regulon, similar to the Spx regulon, is induced in response to disulfide stress (4, 18, 19).


To validate the results obtained with the *ctsR*::mTn insertion, we used the BKE collection (20) to construct a strain harboring a clean deletion of the *ctsR* gene ( $\Delta ctsR$ ), which also contained the  $P_{trxB}$ -*lacZ* reporter fusion. As expected, the  $\Delta ctsR$  null strain displayed whiter colonies than the wild type on LB plates supplemented with X-Gal (Fig. 1A), and ectopic complementation of the  $\Delta ctsR$  null strain with a conditional allele of *ctsR* (i.e.,  $P_{hs}$ -*ctsR*) restored the wild-type phenotype (Fig. 1A and D). In contrast, complementation with the *ctsR*<sup>R63E</sup> allele, which encodes a CtsR protein unable to bind



**FIG 1** Dysregulation of the CtsR regulon leads to reduced induction of the *trxB* promoter, a reporter of Spx activity. (A) Cells with a clean deletion in the *ctsR* gene (i.e.,  $\Delta ctsR$ ) display reduced induction of the Spx-controlled gene *trxB* on LB plates supplemented with X-Gal. The deletion mutant was complemented by ectopic expression of *ctsR* but not *ctsR*<sup>R63E</sup>. (B) Growth curves of WT and  $\Delta ctsR$  strains in LB were monitored by measuring optical density at 600 nm. (C) Induction of the  $P_{trxB}$ -*lacZ* transcriptional fusion throughout the exponential and early stationary phases. (D) Complementation of  $\Delta ctsR$  with an ectopic *ctsR* allele (but not *ctsR*<sup>R63E</sup>) driven from the  $P_{hs}$  promoter restores the WT phenotype during exponential ( $t = 100$  min) and stationary ( $t = 240$  min) phases. \*\*,  $P < 0.01$ ; NS, not significant. (E) Diagram of the CtsR regulon in *B. subtilis*. The triangles illustrate the sites of *mariner* insertion.

DNA (21), was unable to restore the phenotype (Fig. 1A and D). Deletion of *ctsR* did not result in changes in growth (Fig. 1B) but did result in reduced expression of the  $P_{trxB}$ -*lacZ* fusion all along the growth curve (Fig. 1C). These results indicate that  $P_{trxB}$  activity is reduced when the CtsR regulon (Fig. 1E) is derepressed.

***ctsR* inactivation leads to increased proteolysis of Spx by ClpCP.** CtsR represses genes encoding two Clp unfoldases (ClpC and ClpE) as well as the ClpP protease (Fig. 1E). We therefore suspected that Spx levels would be reduced by inactivation of *ctsR*. Indeed, decreased Spx levels were observed in the  $\Delta ctsR$  strain (Fig. 2A), which correlated with the reduced activity of the  $P_{trxB}$  reporter fusion (Fig. 1C). For reasons not clear, we consistently observed that the lowest levels of Spx protein were seen as cells enter transition phase (~140 min) and again in stationary phase (~300 min) (Fig. 1B),



**FIG 2** The phenotype associated with  $\Delta ctsR$  is largely explained by increased ClpCP proteolysis. (A) Spx, ClpX, and ClpC levels in both WT and  $\Delta ctsR$  cells were surveyed during exponential and early stationary phases by Western blotting. The presented blot is representative of four biological replicates. (B) WT,  $\Delta clpX$  (*clpX::spec*),  $\Delta yjbH$  (*yjbH::kan*), and  $\Delta clpP$  (*clpP::tet*) cells in an *spx*<sup>cond</sup> background were assessed for Spx levels during exponential phase (*t* = 100 min); 50  $\mu$ M IPTG was added to the bacterial cultures (*OD*<sub>600</sub> of ~0.1) to induce *spx* expression. When cells reached an *OD*<sub>600</sub> of 0.4 to 0.6, samples were taken for Western blot analyses. ClpC levels were included in panels A and B to illustrate the derepression of the CtsR regulon in  $\Delta ctsR$  cells. This blot is representative of three independent replicates. (C) *P*<sub>trxB</sub> activity was studied on 48-h-old colonies of  $\Delta clpX$  (*clpX::spec*) and  $\Delta clpP$  (*clpP::tet*) strains growing on LB plus X-Gal plates. The colonies were derived from transformations of the *clpX::spec* and *clpP::tet* cassettes into the WT and  $\Delta ctsR$  strains. A *t* test was performed to compare the mean values of each pair of strains. \*, *P* < 0.05; \*\*\*, *P* < 0.001. (D) A chloramphenicol chase was performed in *spx*<sup>cond</sup> cells lacking *clpX*, *clpX clpE*, *clpX clpC*, or *clpP* to determine Spx stability. Cells were grown with IPTG (100  $\mu$ M) to induce *spx* expression and then treated with 100  $\mu$ g ml<sup>-1</sup> of chloramphenicol to stop protein synthesis.  $\Delta clpX$  denotes *clpX::spec*;  $\Delta clpE$  and  $\Delta clpC$  denote *clpE::ery* and *clpC::ery*, respectively;  $\Delta clpP$  denotes *clpP::tet*. The protein levels were quantified using Image Lab 5.2.1 software (Bio-Rad) as described in Materials and Methods. Error bars represent standard errors of the means (SEMs) from at least three independent replicates.

and this effect is the same in both wild-type (WT) and  $\Delta ctsR$  cells (Fig. 2A). In parallel, we monitored the levels of ClpX and ClpC by Western blotting. ClpC, but not ClpX, was significantly elevated in the  $\Delta ctsR$  strain compared to that in the WT (Fig. 2A). This is consistent with CtsR acting as a repressor of *clpC* transcription (Fig. 2A and 1E). We therefore hypothesized that the reduction in Spx in the  $\Delta ctsR$  strain likely involved ClpP proteolysis through the ClpCP or ClpEP proteases, rather than ClpXP, which is generally considered the primary pathway for Spx degradation.


To explore in further detail the basis for the  $\Delta ctsR$  phenotypes, we used a strain with conditional expression of *spx* (i.e.,  $\Delta spx amyE::P_{trxB}-spx$ ), which we called *spx*<sup>cond</sup>, in order to maintain a fixed *spx* transcription rate. To determine if ClpXP was involved in degradation of Spx in the  $\Delta ctsR$  strain, we monitored Spx levels in *spx*<sup>cond</sup> cells lacking either ClpX or the ClpX adaptor protein, YjbH (Fig. 2B). As expected, these cells had significantly elevated levels of Spx, but this level was still reduced in the  $\Delta ctsR$  background. However, Spx levels were unaffected by the *ctsR* mutation in cells lacking ClpP (Fig. 2B). These results are consistent with a role for the ClpP protease in the degradation of Spx. Since a  $\Delta ctsR$  mutation can still modestly reduce *P*<sub>trxB</sub> activity, even

in cells lacking ClpP, this suggests that another member of the CtsR regulon can reduce Spx activity (Fig. 2C; see also Fig. S1), as explored in more detail below.

Next, we used a chloramphenicol chase assay to quantify the contribution of ClpCP or ClpEP to Spx degradation (Fig. 2D). In the WT strain, Spx was rapidly degraded with a half-life of  $\sim 2$  min, as shown previously (14) and confirmed here (see below). Although Spx was much more stable in  $\Delta clpX$  *spx*<sup>cond</sup> cells, it was still degraded, with an approximately  $\sim 60\%$  decrease over 20 min (Fig. 2D). A similar rate of Spx turnover was noted in  $\Delta clpX$  *spx*<sup>cond</sup> cells lacking *clpE* but not in *spx*<sup>cond</sup> cells lacking *clpC* *clpX* or *clpP* (Fig. 2D). Interestingly, although Spx is stable in both the  $\Delta clpX$   $\Delta clpC$  double mutant and the  $\Delta clpP$  background (Fig. 2D), the level of Spx was higher in the latter strain (see Fig. S2). The basis for this difference is not clear but might involve a backup role for ClpEP under these conditions. In sum, we conclude that ClpCP contributes to Spx degradation *in vivo*, and this pathway is likely to be important under conditions where ClpXP degradation is impeded. Indeed, previous biochemical experiments demonstrated that ClpCP is competent to degrade Spx *in vitro* (11).

**The McsB arginine kinase affects Spx activity.** The activity of ClpC relies on adaptor proteins, which help assemble ClpCP and deliver substrates (22). We therefore reasoned that one of those adaptors might account for the ClpP-dependent and/or ClpP-independent phenotypes of  $\Delta ctsR$  cells. In fact, the gene encoding the McsB arginine kinase, one of the ClpC adaptors, lies within the *clpC* operon and was thus also upregulated in the  $\Delta ctsR$  strain (Fig. 1E). McsB activity requires the product of the adjacent gene, *mcsA* (18, 23), and its activity has been shown to be important to both modulate protein activity (21) and mark proteins for ClpCP degradation (24). Our attention was drawn to the possible role of McsB-mediated phosphoarginine modification in Spx regulation due to our recovery of a mariner *ywE::mTn* insertion in our screen for altered expression of *trxB* (Fig. 3A and B; Table S1). YwE functions as a phosphoarginine phosphatase (23, 25), suggesting that an increase in protein phosphorylation likely leads to a decrease in Spx stability and/or activity. As observed for the  $\Delta ctsR$  strain, the phenotype due to inactivation of *ywE* was independent of *spx* transcriptional control and ClpXP-mediated Spx proteolysis (see Fig. S3B). Indeed, Western blotting showed no significant differences of Spx levels between WT and  $\Delta ywE$  strains (Fig. 3C), suggesting that the observed effects (Fig. 3A and B) are the result of changes in Spx activity. The decrease in Spx activity in the  $\Delta ywE$  mutant reverted to WT levels in a  $\Delta ywE$   $\Delta mcsB$  double mutant, which additionally lacks the McsB arginine kinase (Fig. 3B). The effect of a  $\Delta ywE$  mutation was less dramatic than that for the  $\Delta ctsR$  strain (Fig. 3A) and was complemented by an ectopic copy integrated at *amyE* (Fig. S3A). The impact of arginine phosphorylation on the expression of the Spx regulon was previously noted in transcriptomic studies of  $\Delta mcsB$  and  $\Delta ywE$  mutants (26).

In light of the above-described results, we postulated that the reduction in Spx activity in the  $\Delta ctsR$  strain likely reflects a combined effect of increased ClpCP activity and increased activity of the McsA/McsB pathway for protein phosphorylation. Indeed, Spx was shown previously by phosphoproteomics to be phosphorylated on multiple Arg residues (24). We therefore placed either *clpC* alone or the *mcsA*, *mcsB*, and *clpC* genes together, under IPTG (isopropyl- $\beta$ -D-thiogalactopyranoside) control at the native locus using the pMUTIN system. In the  $P_{s_{pac}}-clpC$  strain, induction of ClpC (under conditions where McsA and McsB are expressed from the native *ctsR* promoter) (Fig. 1E) did not lead to a decrease in Spx activity, as judged from the  $P_{trxB}-lacZ$  reporter. When all three genes were placed downstream of the  $P_{s_{pac}}$  promoter (in the  $P_{s_{pac}}-mcsA-mcsB-clpC$  strain), Spx activity was decreased upon induction, although there was also a higher basal level of activity (Fig. 3D). These observations are consistent with the idea that the negative effect of the  $\Delta ctsR$  mutation likely requires the concerted action of McsA, McsB, and the ClpCP-protease. Furthermore, deletion of *mcsB* in the wild-type strain had no effect on  $P_{trxB}$  activity (Fig. 3E), which is consistent with McsB being largely inactive in unstressed cells (27). In contrast, its inactivation in the  $\Delta ctsR$  strain



**FIG 3** Elevated arginine phosphorylation affects Spx activity. (A and B) Cells lacking *ywIE* display reduced induction of the *trxB* promoter, and this phenotype was reversed by deletion of *mcsB*. (C) Spx levels were assessed on WT and  $\Delta ywIE$  cells at mid-exponential phase. This experiment is representative of three biological replicates. (D)  $P_{trxB}$  activity was studied to assess whether altering *clpC* and/or *mcsA-mcsB-clpC* expression levels were sufficient to replicate the difference between WT and  $\Delta ctsR$  cells (Fig. 1D). (E)  $P_{trxB}$  activity was measured to determine the effect of *mcsB* deletion on Spx activity in WT and  $\Delta ctsR$  cells. (F) Spx levels were measured 30 min after treatment of mid-exponential cells with chloramphenicol as described for Fig. 2D. (G) Predicted Spx R-phosphorylation sites according to Trentini et al. (24). The residues that form the redox-sensing switch are included for reference. (H) The contribution of each potentially phosphorylated Arg residue to the  $\Delta ywIE$  phenotype was assessed by replacing them by Lys (i.e., R to K) and measuring  $P_{trxB}$  activity. The ectopic WT or mutant allele of *spx* was induced with IPTG (100  $\mu$ M), and  $P_{trxB}$  activity measured at mid-exponential phase. Error bars represent SEMs from at least three independent replicates. \*,  $P < 0.05$ ; \*\*,  $P < 0.01$ ; \*\*\*,  $P < 0.001$ ; NS, not significant. For panels B, E, and F, one-way analyses of variance (ANOVAs) and Tukey's honestly significant difference (HSD) tests were used to compare the different bacterial strains. For panels D and H, *t* tests were performed to compare the effects of either IPTG addition or deletion of *ywIE*, respectively.

(i.e., the  $\Delta ctsR \Delta mcsB$  double mutant) partially reversed the large decrease in *trxB* expression noted in a  $\Delta ctsR$  strain, and this effect was complemented by ectopic expression of *mcsA* and *mcsB* (Fig. 3E). Taking these results together, we conclude that McsB modulates Spx activity through arginine phosphorylation and may also contrib-


ute to a reduction in stability by acting as an adaptor for Spx proteolysis. The regulatory control of McsA/McsB on Spx thus appears to be critical under conditions that result in induction of the CtsR regulon.

Spx was shown previously to be phosphorylated on four Arg residues: R14, R91, R100, and R112 (24). Inspection of the Spx structure reveals that the first two (R14 and R91) are near the disulfide switch, and the latter two (R100 and R112) are near the putative sites of binding of the YjbH adaptor protein for ClpXP proteolysis (Fig. 3G) (28, 29). The Spx paralog MgsR was phosphorylated on R17 and R95 (24), which align with Spx R14 and R92 in the protein structures. To determine which of these arginines might be relevant to the observed phenotypes of the *mcsB* and *ywE* mutants, we individually replaced each of these Arg residues (and an additional arginine in the disulfide switch region, R92) with lysine (Spx<sup>R14K</sup>, Spx<sup>R91K</sup>, Spx<sup>R92K</sup>, Spx<sup>R100K</sup>, and Spx<sup>R112K</sup>). Induction of some of the Spx variants decreased *trxB* expression compared to that in an isogenic strain harboring the wild-type *spx* allele (Fig. 3H). In all cases, however, cells lacking *ywE* still displayed reduced induction of the reporter fusion, suggesting that no single residue is absolutely required for the reduction in activity of the *ywE* deletion (Fig. 3H).

Analysis of representative *Firmicutes* species further showed that *mcsB* cooccurs with *spx* in some *Bacillales* species, including *B. subtilis*, *Listeria monocytogenes*, and *Staphylococcus aureus* but not in representative *Lactobacillales*. *mcsB* is, however, also present in some species lacking Spx homologs such as *Veillonella parvula* or *Coprococcus catus* (see Table S4). The arginine residues at the positions described in Fig. 3 were highly conserved in the species containing McsB and slightly less conserved in the species lacking McsB (see Fig. S5), which might suggest a potential functional role.

Phosphorylation of arginine residues in some proteins is important for their degradation via ClpCP (24). We therefore hypothesized that increased arginine phosphorylation of Spx might lead to increased Spx degradation in cells lacking ClpX. This was indeed the case, as chloramphenicol chase experiments in a *clpX* strain (to eliminate the major pathway of Spx degradation by ClpXP) lacking YwE showed a modest increase in Spx degradation (Fig. 3F). Unexpectedly, deletion of *mcsB* did not prevent this effect, perhaps suggesting the presence of other pathways for Arg phosphorylation *in vivo* or other roles for YwE. We note that in the absence of McsB other ClpC adaptor proteins (i.e., MecA and YpbH) might play a more prominent role in Spx turnover. In support of this hypothesis, both MecA and McsB were previously shown to interact at the same ClpC site, and competition between these adaptors for ClpCP proteolysis of  $\alpha$ -casein was previously demonstrated *in vitro* (30). Additionally, MecA can accelerate ClpCP-catalyzed degradation *in vitro* (11).

**The toxicity due to Spx accumulation is partially alleviated by deletion of *ctsR* or *ywE*.** Spx accumulation in *B. subtilis*, as observed in  $\Delta yjbH$ ,  $\Delta clpX$ , or  $\Delta clpP$  mutants, results in reduced growth, sporulation, and competence (9, 31). Consistently, overexpression of an IPTG-inducible *spx*<sup>DD</sup> allele, which is resistant to proteolysis, as the only source of Spx for the cells, prevented bacterial growth upon induction (see Fig. S4). We therefore reasoned that if deletion of *ctsR* results in reduced Spx levels,  $\Delta clpX$  cells lacking CtsR should display improved growth. This was indeed the case, since deletion of *ctsR* improved growth (as evidenced by a marked reduction in lag phase) in *spx*<sup>cond</sup>  $\Delta clpX$  cells, but only when *spx* was induced (Fig. 4A). As expected, no improvement in growth was observed upon inactivation of *ctsR* in *spx*<sup>cond</sup>  $\Delta clpP$  cells. These results suggest that derepression of the CtsR regulon alleviates the toxicity imposed by abnormally high Spx levels, a result correlated with reduced Spx levels (Fig. 4A), and also that this effect is due to increased ClpCP-mediated Spx proteolysis. Next, we assessed the effects of deletion of  $\Delta ywE$  in spot dilution assays. Induction of Spx reduced the plating efficiency of the  $\Delta clpX$  strain by  $\sim 10^3$ , as observed in a spot dilution assay on LB with 100  $\mu$ M IPTG (Fig. 4B), consistent with the increased lag seen in growth studies (Fig. 4A). Using this assay as a measure of Spx toxicity, we note that introduction of a  $\Delta ywE$  mutation increased plating efficiency, and this effect was largely dependent on McsB (Fig. 4B), which correlated with our prior observations




**FIG 4** Spx toxicity is alleviated by deletion of *ctsR* or *ywIE*. (A) Growth curves of *spx<sup>cond</sup>*, *spx<sup>cond</sup> ΔclpX*, and *spx<sup>cond</sup> ΔclpP* (genotypes as for Fig. 2B) in absence and presence of 100 μM IPTG. (B) WT, *ΔmcsB*, *ΔywIE*, and *ΔmcsB ΔywIE* cells in a *spx<sup>cond</sup> ΔclpX* genetic background were surveyed on plates with or without 100 μM IPTG. The results are representative of two independent replicates.

(Fig. 3B). Thus, the McsB arginine kinase reduces Spx toxicity, presumably by Spx phosphorylation.

**ClpCP-mediated Spx degradation under disulfide stress.** The present results suggest that ClpCP might be important for Spx degradation under conditions that result in upregulation of the CtsR regulon, such as diamide treatment (19). Importantly, some of the conditions that lead to CtsR derepression, such as disulfide, heat, or ethanol stress, also result in reduced ClpXP-mediated Spx proteolysis (12, 13). We therefore hypothesized that ClpCP-mediated Spx degradation provides a mechanism to detoxify Spx under conditions where the ClpXP pathway for Spx degradation is inactive. To determine if this is the case, we monitored Spx degradation in WT, *ΔclpX*, and *ΔclpC* cells in the presence and absence of diamide. In the WT and *ΔclpC* strains, under unstressed conditions, Spx was rapidly degraded, while degradation occurred slowly in *ΔclpX* cells (Fig. 5). These results confirm the primary role of ClpX in Spx degradation in unstressed cells. In the presence of diamide, Spx degradation was reduced in the WT, which is consistent with inactivation of ClpX and YjbH. Degradation was fully abolished in *ΔclpC* cells, confirming that under disulfide stress, ClpCP is responsible for the residual slow degradation of Spx.

**Spx regulates the expression of the *ctsR* operon.** Using chromatin immunoprecipitation (ChIP)-tilling microarray technology, Rochat et al. showed that Spx binds to and regulates the *ctsR* promoter (4). This interaction, however, was not explored in further detail. To assess the contribution of Spx for induction of the autoregulated *ctsR* operon, we studied the *clpC* mRNA levels in WT, *ΔctsR*, *Δspx*, and *ΔctsR Δspx* cells in response to vancomycin, a potent inducer of the Spx regulon (14). Deletion of *ctsR* resulted in derepression of the *ctsR* operon, which was observed as a more intense







**FIG 5** ClpCP-mediated Spx degradation under disulfide stress. Spx stability was assessed in the absence or presence of diamide in the WT,  $\Delta clpC$ , and  $\Delta clpX$  strains. Exponentially growing cells were treated or not with 0.5 mM diamide to induce Spx accumulation, protein synthesis was stopped with chloramphenicol, and Spx levels determined by Western blotting as described above for Fig. 2D. Each point represents the average from three biological replicates. Bars indicate the SEMs from biological replicates.

band at the initial time point and is consistent with negative autoregulation. This deletion, however, did not abolish the activation of the operon in response to cell envelope stress (Fig. 6). Conversely, deletion of Spx largely suppressed this activation, suggesting that both CtsR and Spx both regulate the *ctsR* operon. As a control, we studied another CtsR-regulated gene (i.e., *clpE*), which was also reported to be under Spx control; however, no contribution of Spx to *clpE* expression was observed (Fig. 6). Taken together, the present evidence demonstrates that Spx, which is activated by cell envelope and disulfide stress, can contribute to increased expression of the CtsR regulon, which, in turn, includes critical mediators of Spx proteolysis and activity (Fig. 7).

**Concluding remarks.** Spx is a pleiotropic transcription factor in *B. subtilis*, which is activated in response to proteotoxic and cell wall stress conditions (1, 5, 12, 14, 19, 32). The regulatory pathways that coordinate Spx activity are intricate and involve many cellular partners (5–7, 9, 11, 14, 33, 34). Here, using an unbiased screen, we identify two



**FIG 6** Both Spx and CtsR drive the expression of the *ctsR* operon. Northern blot showing the expression of two CtsR-regulated genes in response to vancomycin. Exponentially growing cells were treated with  $1 \mu\text{g ml}^{-1}$  vancomycin, and RNA was harvested before vancomycin treatment ( $t = 0$  min) and after 10 min and 30 min. RNA was run in a denaturing agarose gel, transferred to a Z probe membrane, and detected with biotin-labeled RNA probes. This experiment was performed in duplicates with identical results.



**FIG 7** Model of Spx regulation in *B. subtilis* including pathways for Spx synthesis, degradation, and posttranslational modifications. Several promoters, controlled by different RNA polymerase holoforms, and two repressors regulate the transcription of *spx*. In unstressed cells, Spx is rapidly degraded through the ClpXP-YjbH system. Under cell wall stress, the YirB antiadaptor is induced and antagonizes YjbH, thus preventing Spx proteolysis. The ClpCP protease also contributes to Spx degradation. ClpCP-mediated Spx proteolysis appears to be at least in part mediated by McsB, an arginine kinase that acts as an adaptor for ClpCP. Spx activity is also modulated by changes in the oxidation state of the redox-sensing switch and also perhaps through Arg phosphorylation. The inactivation of Spx in cells lacking the YwIE arginine phosphatase suggests a negative role for Arg phosphorylation. Activation of the *ctsR* operon by Spx can increase levels of ClpCP and the arginine phosphorylation system, thereby providing a negative feedback loop.

genes whose deletion leads to reduced Spx stability and activity: (i) *ctsR*, the master regulator of proteolysis gene (17), and (ii) *ywIE*, the *B. subtilis* arginine phosphatase gene (23, 25). Characterization of these genes uncovered novel molecular mechanisms associated with Spx regulation. First, by studying the  $\Delta ctsR$  phenotype, we found that ClpCP is also capable of degrading Spx *in vivo* (Fig. 2), particularly under conditions that potentially lead to inactivation of the ClpXP-YjbH system (Fig. 5). Moreover, McsB, a ClpC adaptor and arginine kinase, appears to be important for this process (Fig. 3). Both *clpC* and *mcsB* are members of the CtsR regulon (35). A second gene identified in our transposon screening encodes YwIE, an arginine phosphatase that antagonizes the action of the McsB protein arginine kinase (27). Interestingly, the *ywIE* phenotype was fully reverted in the double  $\Delta ywIE \Delta mcsB$  mutant, thus implicating the kinase activity of McsB in the regulation of Spx (23, 25). Inactivation of *ywIE* had no effect on Spx levels, leading us to conclude that elevated arginine phosphorylation as observed in the  $\Delta ywIE$  strain primarily affects Spx activity (Fig. 3). Indeed, phosphorylation of several arginine residues on Spx and its paralog, MgsR, was previously observed in phosphoproteomic studies, which appears to support a direct effect of McsB on Spx (24). Analysis of Spx turnover in cells lacking the ClpXP pathway also revealed increased Spx proteolysis in  $\Delta ywIE$  cells, therefore suggesting that increased arginine phosphorylation might also affect Spx degradation.

The relationship between the CtsR and Spx regulons is, however, not unidirectional. In this work, we further show that Spx, together with CtsR, regulates the expression of the *ctsR* operon (Fig. 6); the positive correlation observed between the expression profile of CtsR- and Spx-regulated genes (i.e., *nfrA* and *msrA*) further strengthens this connection (19). The biological significance of this connection lies in the fact that both regulons are critical for degradation and/or refolding of damaged or misfolded proteins; this effect might be achieved through upregulation of the Clp proteases, the arginine phosphorylation system, the thioredoxin system, and other redox-associated proteins (1, 4, 35). Oxidative stress, which can lead to activation of both the Spx and CtsR operons, also leads to the inactivation of the arginine phosphatase activity of YwIE (36). These results thus suggest that Spx and CtsR participate in a feedback loop in which Spx contributes to the activation of the CtsR regulon and that the latter mediates the inactivation of Spx (Fig. 7). This regulatory circuit might be beneficial for the cells, since it enables the simultaneous activation of the Spx and CtsR regulons while preventing the negative effects of Spx overaccumulation (9, 31, 37). Interestingly, those proteotoxic stresses that lead to activation of the Spx regulon, as well as the CtsR regulon, also inactivate Spx proteolysis through ClpXP (12, 13). Consistent with a role for the CtsR regulon in Spx inactivation, we observed that in cells lacking the ClpXP protease, either CtsR derepression, which leads to increased ClpCP proteolysis, or deletion of *ywIE*, which leads to elevated arginine phosphorylation, prevents the deleterious effects of Spx accumulation (Fig. 4). ClpCP proteolysis, by contrast, does not appear to be affected by diamide treatment (Fig. 5) and, based on its transcription profile, is not predicted to be inactivated under other proteotoxic stress conditions (19). Altogether, these observations suggest a critical role of Spx in activation of the CtsR regulon and of the CtsR regulon in preventing Spx toxicity. This role appears to involve both arginine phosphorylation profiles and increased ClpCP-mediated degradation. The present model of Spx regulation, however, does not account for all the observed phenotypes, suggesting that even further mechanisms are at play. The intrinsic complexity of *B. subtilis* Spx regulation is reminiscent of the convoluted regulation of *Escherichia coli* RpoS (38, 39).

## MATERIALS AND METHODS

**Bacterial strains and culture conditions.** All bacterial strains are listed in Table S2 in the supplemental material. *Bacillus subtilis* strains (all based on the *B. subtilis* 168 wild type) were grown under standard conditions: lysogeny broth (LB; 10 g tryptone, 5 g yeast extract, and 5 g NaCl per liter) at 37°C with vigorous shaking, unless otherwise stated. *Escherichia coli* DH5 $\alpha$  was used for plasmid construction. Antibiotics were added to the growth medium when appropriate: 100  $\mu$ g ml<sup>-1</sup> ampicillin for *E. coli*, and 1  $\mu$ g ml<sup>-1</sup> erythromycin plus 25  $\mu$ g ml<sup>-1</sup> of lincomycin (macrolide-lincomycin-streptogramin B [MLS] resistance), 10  $\mu$ g ml<sup>-1</sup> chloramphenicol, 100  $\mu$ g ml<sup>-1</sup> spectinomycin, and 10  $\mu$ g ml<sup>-1</sup> kanamycin for *B. subtilis*.

**Transformation of *Bacillus subtilis*.** For genetic transformation of *B. subtilis*, a suspension of cells (optical density at 600 nm [OD<sub>600</sub>] of ~0.1) was prepared in 5.0 ml of medium A [1.0 g yeast extract, 0.2 g Casamino Acids, 5.0 g glucose, 2.0 g (NH<sub>4</sub>)SO<sub>4</sub>, 18.3 g K<sub>2</sub>HPO<sub>4</sub>·3H<sub>2</sub>O, 6 g KH<sub>2</sub>PO<sub>4</sub>, 1 g Na citrate, and 0.2 g MgSO<sub>4</sub>·7H<sub>2</sub>O per liter] using an overnight culture of cells growing on LB plates as initial culture. This suspension was then incubated at 37°C with vigorous shaking for ~4 h, which corresponded to 1.5 h after the end of the exponential phase, as determined by OD<sub>600</sub> measurements. Then, 100  $\mu$ l of this culture was transferred to a 5-ml tube containing 400  $\mu$ l of prewarmed medium B (i.e., medium A plus 250  $\mu$ M MgCl<sub>2</sub> plus 250  $\mu$ M CaCl<sub>2</sub>) and incubated for a further 90 min. Next, 200 ng of genomic DNA or 500 ng of plasmid DNA was added to the bacterial culture, unless otherwise stated, and cells were incubated for a further 2 h. Cells were plated on LB plates supplemented with the corresponding antibiotic. For transformation of pMUTIN-based constructs, the concentrations of erythromycin and spectinomycin were reduced to 0.5  $\mu$ g ml<sup>-1</sup> and 50  $\mu$ g ml<sup>-1</sup>, respectively.

**Cloning and site-directed mutagenesis.** For cloning purposes, the PCRs were performed using the high-fidelity Phusion DNA polymerase (NEB) according to the manufacturer's instructions and genomic DNA of *B. subtilis* HB18501 unless otherwise stated. The primers used in this study are listed in Table S3. The details regarding strain constructions are described in the supplemental material.

**Transposon library.** *B. subtilis* cells with the appropriate genotype were transformed with the pMarA plasmid, plated on LB plus 0.3 mg ml<sup>-1</sup> erythromycin, and incubated at 28°C for 48 h. The resulting transformants were stored at -80°C (host for transposition). Cells containing the pMarA plasmid were then grown overnight at 28°C in LB supplemented with kanamycin and erythromycin. A new culture (1:40) was started in LB plus kanamycin (to select for the transposition events) and incubated for 4 h at 28°C; the cells were then transferred at 37°C and incubated for three more hours, and finally plated on

LB amended with 15  $\mu\text{g ml}^{-1}$  kanamycin and 0.2  $\text{mg ml}^{-1}$  X-Gal. Plates were incubated at 42°C for loss of the plasmid, and then candidate mutant colonies were selected on the basis of the intensity of its blue color. Whiter colonies on the plates were chosen and subjected to one more round of selection; finally, 30 clones from each library were saved for further studies. To determine the site of *mariner* insertion, chromosomal DNA was isolated using the DNeasy kit (Qiagen) and digested with the *Taq* $\alpha$ 1 restriction enzyme, and the products ligated using the T4 ligase. The resulting DNA was used as the template for an inverse PCR using the primers 6299 and 6300 annealing the *mariner* transposon. The PCR products were in-column cleaned and analyzed by sequencing using the 6301 internal primer. The sequencing information was then used to map the transposon insertion site.

**$\beta$ -Galactosidase activity.** The cells were grown until the  $\text{OD}_{600}$  reached  $\sim 0.5$ . Then, cells were treated with different chemicals or not treated and incubated at 37°C with agitation. At specific time points, samples were taken, washed twice in phosphate-buffered saline (PBS), and finally resuspended in 900  $\mu\text{l}$  of Z buffer (60 mM  $\text{Na}_2\text{HPO}_4$ , 40 mM  $\text{NaH}_2\text{PO}_4$ , 10 mM KCl, 1 mM  $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$ ) supplemented with 400  $\mu\text{M}$  dithiothreitol (DTT). Alternatively, several colonies were recovered from the plate and resuspended in PBS at an  $\text{OD}_{600}$  of  $\sim 0.5$ , washed in PBS, and resuspended in 900  $\mu\text{l}$  of Z buffer plus 400  $\mu\text{M}$  DTT for further experiments. Optical density at 600 nm was measured, and then the cells were lysed using 100  $\mu\text{g ml}^{-1}$  lysozyme at 37°C for 30 min. Next, 200  $\mu\text{l}$  of 4  $\text{mg ml}^{-1}$  *o*-nitrophenyl- $\beta$ -D-galactopyranoside (ONPG) was added to the lysate, and the reaction mixture was incubated at 28°C until the samples produced a visible yellow color. The reaction was stopped by adding 500  $\mu\text{l}$  of 1.0 M  $\text{Na}_2\text{CO}_3$ . The absorbance was then measured at 420 nm and 550 nm, and  $\beta$ -galactosidase activity was determined using the following equation: Miller units =  $1,000 \times (\text{OD}_{420} - 1.75 \times \text{OD}_{550}) / (t \times v \times \text{OD}_{600})$ , where  $t$  is time in minutes and  $v$  is the volume of culture used in the reaction.

**Western blots.** A total of 5 ml of cells was collected, washed in PBS, and resuspended in 150  $\mu\text{l}$  of disruption buffer (20 mM Tris-HCl [pH 8.0], 100 mM NaCl, 1 mM EDTA, 5% glycerol) supplemented with the cOmplete EDTA-free protease inhibitor cocktail. The cells were disrupted by sonication and then centrifuged for 15 min at 13,500 rpm at 4°C. The soluble fraction was collected and quantified using the Bradford assay. Reducing sample buffer was added to the protein extract, and then 5  $\mu\text{g}$  of protein was loaded in a 4% to 20% SDS-PAGE gel. Proteins were transferred onto a polyvinylidene difluoride (PVDF) membrane using the TransBlot Turbo transfer system (Bio-Rad, USA). The membrane was blocked using 5% protein blotting blocker dissolved in Tris-buffered saline with Tween 20 (TTBS) for 1 h at room temperature (RT). Then, the primary antibodies were resuspended in 0.5% protein blotting blocker dissolved in TTBS and incubated for 16 h at 4°C. Finally, an anti-rabbit horseradish peroxidase (HRP)-conjugated secondary antibody was added and incubated for 2 h at RT. The membrane was revealed using the Clarity Western ECL substrate and visualized in a gel documenter. For quantification of Sp $\chi$ , the intensity of the bands was measured using Image Lab 5.2.1 software (Bio-Rad, USA).

**Chloramphenicol chase assay.** Cells (50 ml) were grown under standard conditions up to an optical density at 600 nm of 0.500. Then, the culture was divided and left untreated or treated with 0.5 mM diamide. Next, chloramphenicol was added to the culture medium at a 100  $\mu\text{g ml}^{-1}$  final concentration to stop protein synthesis, using as stock a 20  $\text{mg ml}^{-1}$  chloramphenicol solution dissolved in 95% ethanol. Protein degradation was stopped by treatment with cold trichloroacetic acid (TCA; final concentration 10% TCA), and the amount of protein was normalized by optical density. Cells were then washed twice with ice-cold acetone and left to air dry for 10 min at room temperature. The pellet was resuspended into 100  $\mu\text{l}$  of 1 $\times$  Laemmli buffer, and 10- $\mu\text{l}$  samples of the lysate were loaded in a 4% to 20% acrylamide gel. Protein degradation was then studied by Western blotting. For quantification of protein degradation, the Western blot bands were measured using Image Lab 5.2.1 software (Bio-Rad, USA) and normalized against the SDS-PAGE gel. For normalization, a total of 10 bands from the SDS-PAGE gel were quantified by densitometry and used to determine the amount of total protein loaded in each lane of the gel.

**RNA isolation and Northern blots.** RNA isolation and Northern blotting were carried out as previously described (5, 14). RNA probes were synthesized from PCR products using *in vitro* transcription as previously described (5, 14), with the exception that biotin-16-UTP was used for labeling the probes. The generated RNA blots were developed using the North2South chemiluminescent hybridization and detection kit as per the manufacturer's instructions (Thermo Scientific). The template PCR product for the *clpC* RNA probe was generated using the primers DR309 and DR310, while for the *clpE* RNA probe, we used DR302 and DR303.

**Growth curves and spot dilution assays.** For growth curves, cells (5 ml) were grown under standard conditions to an optical density at 600 nm of  $\sim 0.500$ . Then, cells were resuspended at a final  $\text{OD}_{600}$  of  $\sim 0.01$  in fresh sterile LB supplemented or not with IPTG, and samples of 150  $\mu\text{l}$  were placed in a 96-well plate. Optical density at 600 nm was monitored for 20 h at 37°C with continuous shaking in a Synergy H1 microplate reader (BioTek). For spot dilution assays, cells (5 ml) were grown under standard conditions up to an optical density at 600 nm of  $\sim 0.500$  and serially diluted in sterile LB. The different dilutions were plated on LB plates supplemented or not with IPTG.

## SUPPLEMENTAL MATERIAL

Supplemental material for this article may be found at <https://doi.org/10.1128/JB.00151-19>.

**SUPPLEMENTAL FILE 1**, PDF file, 2.1 MB.

## ACKNOWLEDGMENTS

We thank Ulf Gerth for the anti-ClpX and anti-ClpC serum and Peter Zuber for the anti-Spx serum. We thank Camila Bustos, Manuela Alvarado, and Hye-Rim Hong for their valuable contributions to this work.

This work was supported by a grant from the National Institutes of Health (R35GM122461) to J.D.H.

## REFERENCES

- Nakano S, Küster-Schöck E, Grossman AD, Zuber P. 2003. Spx-dependent global transcriptional control is induced by thiol-specific oxidative stress in *Bacillus subtilis*. *Proc Natl Acad Sci U S A* 100:13603–13608. <https://doi.org/10.1073/pnas.2235180100>.
- Nakano S, Erwin KN, Ralle M, Zuber P. 2005. Redox-sensitive transcriptional control by a thiol/disulphide switch in the global regulator, Spx. *Mol Microbiol* 55:498–510. <https://doi.org/10.1111/j.1365-2958.2004.04395.x>.
- Newberry KJ, Nakano S, Zuber P, Brennan RG. 2005. Crystal structure of the *Bacillus subtilis* anti-alpha, global transcriptional regulator, Spx, in complex with the alpha C-terminal domain of RNA polymerase. *Proc Natl Acad Sci U S A* 102:15839–15844. <https://doi.org/10.1073/pnas.0506592102>.
- Rochat T, Nicolas P, Delumeau O, Rabatinova A, Korelusova J, Leduc A, Bessieres P, Dervyn E, Krasny L, Noirot P. 2012. Genome-wide identification of genes directly regulated by the pleiotropic transcription factor Spx in *Bacillus subtilis*. *Nucleic Acids Res* 40:9571–9583. <https://doi.org/10.1093/nar/gks755>.
- Rojas-Tapias DF, Helmann JD. 2018. Induction of the Spx regulon by cell wall stress reveals novel regulatory mechanisms in *Bacillus subtilis*. *Mol Microbiol* 107:659–674. <https://doi.org/10.1111/mmi.13906>.
- Antelmann H, Scharf C, Hecker M, Hecker M. 2000. Phosphate starvation-inducible proteins of *Bacillus subtilis*: proteomics and transcriptional analysis. *J Bacteriol* 182:4478–4490. <https://doi.org/10.1128/JB.182.16.4478-4490.2000>.
- Leelakriangsak M, Zuber P. 2007. Transcription from the P<sub>3</sub> promoter of the *Bacillus subtilis* spx gene is induced in response to disulfide stress. *J Bacteriol* 189:1727–1735. <https://doi.org/10.1128/JB.01519-06>.
- Zuber P. 2009. Management of oxidative stress in *Bacillus*. *Annu Rev Microbiol* 63:575–597. <https://doi.org/10.1146/annurev.micro.091208.073241>.
- Larsson JT, Rogstam A, Wachenfeldt von C. 2007. YjbH is a novel negative effector of the disulphide stress regulator, Spx, in *Bacillus subtilis*. *Mol Microbiol* 66:669–684. <https://doi.org/10.1111/j.1365-2958.2007.05949.x>.
- Garg SK, Kommineni S, Henslee L, Zhang Y, Zuber P. 2009. The YjbH protein of *Bacillus subtilis* enhances ClpXP-catalyzed proteolysis of Spx. *J Bacteriol* 191:1268–1277. <https://doi.org/10.1128/JB.01289-08>.
- Nakano S, Zheng G, Nakano MM, Zuber P. 2002. Multiple pathways of Spx (YjbD) proteolysis in *Bacillus subtilis*. *J Bacteriol* 184:3664–3670. <https://doi.org/10.1128/JB.184.13.3664-3670.2002>.
- Engman J, Wachenfeldt von C. 2015. Regulated protein aggregation: a mechanism to control the activity of the ClpXP adaptor protein YjbH. *Mol Microbiol* 95:51–63. <https://doi.org/10.1111/mmi.12842>.
- Zhang Y, Zuber P. 2007. Requirement of the zinc-binding domain of ClpX for Spx proteolysis in *Bacillus subtilis* and effects of disulfide stress on ClpXP activity. *J Bacteriol* 189:7669–7680. <https://doi.org/10.1128/JB.00745-07>.
- Rojas-Tapias DF, Helmann JD. 2018. Stabilization of *Bacillus subtilis* Spx under cell wall stress requires the anti-adaptor protein YirB. *PLoS Genet* 14:e1007531. <https://doi.org/10.1371/journal.pgen.1007531>.
- Kommineni S, Garg SK, Chan CM, Zuber P. 2011. YjbH-enhanced proteolysis of Spx by ClpXP in *Bacillus subtilis* is inhibited by the small protein YirB (YuzO). *J Bacteriol* 193:2133–2140. <https://doi.org/10.1128/JB.01350-10>.
- Kruger E, Hecker M. 1998. The first gene of the *Bacillus subtilis* clpC operon, *ctsR*, encodes a negative regulator of its own operon and other class III heat shock genes. *J Bacteriol* 180:6681–6688.
- Derré I, Rapoport G, Msadek T. 1999. CtsR, a novel regulator of stress and heat shock response, controls clp and molecular chaperone gene expression in Gram-positive bacteria. *Mol Microbiol* 31:117–131. <https://doi.org/10.1046/j.1365-2958.1999.01152.x>.
- Elsholz AKW, Hempel K, Pöther D-C, Becher D, Hecker M, Gerth U. 2011. CtsR inactivation during thiol-specific stress in low GC, Gram<sup>+</sup> bacteria. *Mol Microbiol* 79:772–785. <https://doi.org/10.1111/j.1365-2958.2010.07489.x>.
- Nicolas P, Mäder U, Dervyn E, Rochat T, Leduc A, Pigeonneau N, Bidnenko E, Marchadier E, Hoebeke M, Aymerich S, Becher D, Bisicchia P, Botella E, Delumeau O, Doherty G, Denham EL, Fogg MJ, Fromion V, Goelzer A, Hansen A, Härtig E, Harwood CR, Homuth G, Jarmer H, Jules M, Klipp E, Le Chat L, Leconte F, Lewis P, Liebermeister W, March A, Mars RA, Nannapaneni P, Noone D, Pohl S, Rinn B, Rügheimer F, Sappa PK, Samson F, Schaffer M, Schwikowski B, Steil L, Stülke J, Wiegert T, Devine KM, Wilkinson AJ, van Dijl JM, Hecker M, Völker U, Bessières P, Noirot P. 2012. Condition-dependent transcriptome reveals high-level regulatory architecture in *Bacillus subtilis*. *Science* 335:1103–1106. <https://doi.org/10.1126/science.1206848>.
- Koo B-M, Kritikos G, Farelli JD, Todor H, Tong K, Kimsey H, Wapinski I, Galardini M, Cabal A, Peters JM, Hachmann A-B, Rudner DZ, Allen KN, Typas A, Gross CA. 2017. Construction and analysis of two genome-scale deletion libraries for *Bacillus subtilis*. *Cell Syst* 4:291.e7–305.e7. <https://doi.org/10.1016/j.cels.2016.12.013>.
- Fuhrmann J, Schmidt A, Spiess S, Lehner A, Turgay K, Mechtler K, Charpentier E, Clausen T. 2009. McsB is a protein arginine kinase that phosphorylates and inhibits the heat-shock regulator CtsR. *Science* 324:1323–1327. <https://doi.org/10.1126/science.1170088>.
- Kirstein J, Molière N, Dougan DA, Turgay K. 2009. Adapting the machine: adaptor proteins for Hsp100/Clp and AAA<sup>+</sup> proteases. *Nat Rev Microbiol* 7:589–599. <https://doi.org/10.1038/nrmicro2185>.
- Kirstein J, Zuhlke D, Gerth U, Turgay K, Hecker M. 2005. A tyrosine kinase and its activator control the activity of the CtsR heat shock repressor in *B. subtilis*. *EMBO J* 24:3435–3445. <https://doi.org/10.1038/sj.emboj.7600780>.
- Trentini DB, Suskiewicz MJ, Heuck A, Kurzbauer R, Deszcz L, Mechtler K, Clausen T. 2016. Arginine phosphorylation marks proteins for degradation by a Clp protease. *Nature* 539:48–53. <https://doi.org/10.1038/nature20122>.
- Fuhrmann J, Mierzwa B, Trentini DB, Spiess S, Lehner A, Charpentier E, Clausen T. 2013. Structural basis for recognizing phosphoarginine and evolving residue-specific protein phosphatases in Gram-positive bacteria. *Cell Rep* 3:1832–1839. <https://doi.org/10.1016/j.celrep.2013.05.023>.
- Elsholz AKW, Turgay K, Michalik S, Hessling B, Gronau K, Oertel D, Mader U, Bernhardt J, Becher D, Hecker M, Gerth U. 2012. Global impact of protein arginine phosphorylation on the physiology of *Bacillus subtilis*. *Proc Natl Acad Sci U S A* 109:7451–7456. <https://doi.org/10.1073/pnas.1117483109>.
- Elsholz AKW, Hempel K, Michalik S, Gronau K, Becher D, Hecker M, Gerth U. 2011. Activity control of the ClpC adaptor McsB in *Bacillus subtilis*. *J Bacteriol* 193:3887–3893. <https://doi.org/10.1128/JB.00079-11>.
- Al-Eryani Y, Ib Rasmussen M, Kjellström S, Højrup P, Emanuelsson C, Wachenfeldt von C. 2016. Exploring structure and interactions of the bacterial adaptor protein YjbH by crosslinking mass spectrometry. *Proteins* 84:1234–1245. <https://doi.org/10.1002/prot.25072>.
- Chan CM, Hahn E, Zuber P. 2014. Adaptor bypass mutations of *Bacillus subtilis* spx suggest a mechanism for YjbH-enhanced proteolysis of the regulator Spx by ClpXP. *Mol Microbiol* 93:426–438. <https://doi.org/10.1111/mmi.12671>.
- Kirstein J, Dougan DA, Gerth U, Hecker M, Turgay K. 2007. The tyrosine kinase McsB is a regulated adaptor protein for ClpCP. *EMBO J* 26:2061–2070. <https://doi.org/10.1038/sj.emboj.7601655>.
- Nakano MM, Hajarizadeh F, Zhu Y, Zuber P. 2001. Loss-of-function mutations in *yjbD* result in ClpX- and ClpP-independent competence development of *Bacillus subtilis*. *Mol Microbiol* 42:383–394. <https://doi.org/10.1046/j.1365-2958.2001.02639.x>.

32. Runde S, Molière N, Heinz A, Maisonneuve E, Janczikowski A, Elsholz AKW, Gerth U, Hecker M, Turgay K. 2014. The role of thiol oxidative stress response in heat-induced protein aggregate formation during thermotolerance in *Bacillus subtilis*. *Mol Microbiol* 91:1036–1052. <https://doi.org/10.1111/mmi.12521>.
33. Leelakriangsak M, Kobayashi K, Zuber P. 2007. Dual negative control of *spx* transcription initiation from the P<sub>3</sub> promoter by repressors PerR and YodB in *Bacillus subtilis*. *J Bacteriol* 189:1736–1744. <https://doi.org/10.1128/JB.01520-06>.
34. Jarvis AJ, Thackray PD, Houston CW, Horsburgh MJ, Moir A. 2007. SigM-responsive genes of *Bacillus subtilis* and their promoters. *J Bacteriol* 189:4534–4538. <https://doi.org/10.1128/JB.00130-07>.
35. Elsholz AKW, Gerth U, Hecker M. 2010. Regulation of CtsR activity in low GC, Gram<sup>+</sup> bacteria. *Adv Microb Physiol* 57:119–144. <https://doi.org/10.1016/B978-0-12-381045-8.00003-5>.
36. Fuhrmann J, Subramanian V, Kojetin DJ, Thompson PR. 2016. Activity-based profiling reveals a regulatory link between oxidative stress and protein arginine phosphorylation. *Cell Chem Biol* 23:967–977. <https://doi.org/10.1016/j.chembiol.2016.07.008>.
37. Schäfer H, Heinz A, Sudzinová P, Voß M, Hantke I, Krásný L, Turgay K. 2019. Spx, the central regulator of the heat and oxidative stress response in *B. subtilis*, can repress transcription of translation-related genes. *Mol Microbiol* 111:514–533. <https://doi.org/10.1111/mmi.14171>.
38. Bougdour A, Cuning C, Baptiste PJ, Elliott T, Gottesman S. 2008. Multiple pathways for regulation of  $\sigma^S$  (RpoS) stability in *Escherichia coli* via the action of multiple anti-adaptors. *Mol Microbiol* 68:298–313. <https://doi.org/10.1111/j.1365-2958.2008.06146.x>.
39. Battesti A, Majdalani N, Gottesman S. 2011. The RpoS-mediated general stress response in *Escherichia coli*. *Annu Rev Microbiol* 65:189–213. <https://doi.org/10.1146/annurev-micro-090110-102946>.